Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan.


Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 10 12 2021
revised: 11 01 2022
accepted: 14 01 2022
pubmed: 26 1 2022
medline: 17 3 2022
entrez: 25 1 2022
Statut: ppublish

Résumé

Delta variant of concern (VOC) is the current predominant severe acute respiratory coronavirus type 2 strain causing coronavirus disease 2019 (COVID-19); however, information regarding the impact of the Delta VOC on clinical features and outcomes in pediatric patients with COVID-19 is limited. We conducted a retrospective observational study using the data of patients <18 years of age in COVIREGI-JP, the COVID-19 registry in Japan. The patients were divided into two groups according to the timing of enrollment in the registry (pre-Delta VOC era, October 2020 to May 2021; and Delta VOC era, August to October 2021), and the clinical characteristics and outcomes were compared between the two groups. During the study period, 950 and 349 pediatric patients were registered in the pre-Delta VOC and Delta VOC eras, respectively. The median patient age was younger and the proportion of patients with underlying diseases was higher in the Delta VOC era than that in the pre-Delta VOC era (10.0 vs 7.0 years, P < 0.001, and 7.4% [n = 70] vs. 12.6% [n = 44], P = 0.004, respectively). Significantly more patients were admitted to the intensive care unit in the Delta VOC era than in the pre-Delta VOC era (1.4% [ n = 5] vs. 0.1% [n = 1], P = 0.006), but no patient in either group died or required mechanical ventilation or extracorporeal membrane oxygenation throughout the study period, suggesting that the overall outcomes in children with COVID-19 remained favorable even in the Delta VOC era in Japan.

Identifiants

pubmed: 35074258
pii: S1341-321X(22)00022-8
doi: 10.1016/j.jiac.2022.01.009
pmc: PMC8769918
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

591-594

Informations de copyright

Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Références

Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1249-1254
pubmed: 34499628
J Pediatric Infect Dis Soc. 2021 Dec 31;10(12):1097-1100
pubmed: 34487185
Transl Pediatr. 2020 Dec;9(6):873-875
pubmed: 33457311
Clin Infect Dis. 2021 Dec 6;73(11):e3677-e3689
pubmed: 32986793
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
Cell Mol Life Sci. 2016 Dec;73(23):4433-4448
pubmed: 27392606

Auteurs

Kensuke Shoji (K)

Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan. Electronic address: shoji-k@ncchd.go.jp.

Takayuki Akiyama (T)

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.

Shinya Tsuzuki (S)

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Nobuaki Matsunaga (N)

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.

Yusuke Asai (Y)

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.

Setsuko Suzuki (S)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Noriko Iwamoto (N)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Takanori Funaki (T)

Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan.

Norio Ohmagari (N)

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH